Current Report Filing (8-k)
May 03 2022 - 3:26PM
Edgar (US Regulatory)
0001552189
false
0001552189
2022-05-03
2022-05-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
Form
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 3, 2022
PANACEA
LIFE SCIENCES HOLDINGS, INC.
(Exact
name of the registrant as specified in its charter)
Nevada |
|
001-38190 |
|
27-1085858 |
(State
or other jurisdiction of |
|
(Commission |
|
(IRS
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
5910
South University Blvd, C18-193
Greenwood
Village, CO 80121
(Address
of principal executive offices) (Zip code)
Registrant’s
telephone number, including area code: 1-800-985-0515
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under
any of the following provisions (see General Instruction A.2 below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
symbol(s) |
|
Name
of exchange on which registered |
N/A |
|
N/A |
|
N/A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure.
On
May 3, 2022, Ms. Leslie Buttorff, Chief Executive Officer of Panacea Life Sciences Holdings, Inc. made a presentation to certain members
of the investment community. A copy of such presentation is being furnished herewith as Exhibit 99.1 to this report.
The
information in this Item 7.01 of this report, including the information in the presentation attached as Exhibit 99.1 to this report,
is furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this report, including
the information in the presentation attached as Exhibit 99.1 to this report, shall not be deemed to be incorporated by reference in the
filings of the registrant under the Securities Act of 1933, or the Exchange Act.
Item 9.01 Financial Statements and Exhibits
(d)
Exhibits.
Exhibit
No. |
|
Exhibit |
|
|
|
99.1 |
|
Investor Presentation |
|
|
|
104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on behalf of the
undersigned hereunto duly authorized.
|
Panacea
Life Sciences Holdings, Inc. |
|
|
|
By: |
/s/
Leslie Buttorff |
Date:
May 3, 2022 |
Name: |
Leslie
Buttorff |
|
Title: |
Chief
Executive Officer |
Panacea Life Sciences (PK) (USOTC:PLSH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Panacea Life Sciences (PK) (USOTC:PLSH)
Historical Stock Chart
From Jul 2023 to Jul 2024